Introduction {#sec1_1}
============

Acute kidney injury (AKI) is a life-threatening disorder, although the rate of AKI in COVID-19 is relatively rare. According to reports from Wuhan, China, among 138 hospitalized patients with COVID-19, only 5 (3.6%) patients developed AKI and 2 (1.5%) patients required continuous renal replacement therapy (CRRT) \[[@B1]\]. There are no data about managing CRRT, including prevention of secondary infection and control (IPC) in COVID-19 patients. Here, we report a case of a patient with severe COVID-19 who required CRRT.

Case {#sec1_2}
====

A septuagenarian male suffering from COVID-19 was referred to our hospital. On day 3, tracheal intubation was performed and mechanical ventilation was initiated. His sCre gradually decreased from 1.34 mg/dL (day 1) to 1.06 mg/dL (day 6). As the urine output gradually decreased, sCre increased from day 7 and reached 3.46 mg/dL on day 9, when CRRT was initiated. Nafamostat mesylate was used for anticoagulation. Cytokine-absorbing polymethyl methacrylate membrane \[[@B2], [@B3]\] was used as a hemofilter. During the management of CRRT, there is a risk of the presence of the virus in the CRRT effluent \[[@B4]\]. To evaluate this possibility, we measured SARS-CoV-2 genetic material in the CRRT effluent by qRT-PCR at 5 different time points on 2 days (day 11 and day 14). Real-time RT-PCR for 2019-nCoV was performed at the National Institute of Infectious Diseases \[[@B5]\]. A very weak but positive RT-PCR result was detected in 3 of 5 specimens (Table [1](#T1){ref-type="table"}). We disposed the CRRT effluent in a container using fluid coagulant agent, closed the lid, and treated it as hazardous waste. Though the patient developed anuria, X-ray showed better aeration with continuous removal of water by CRRT, and the patient was extubated on day 22.

Discussion {#sec1_3}
==========

According to a recent report from Wuhan, China, among 52 critically ill adult patients with COVID-19 pneumonia who were admitted to the ICU, 12 (23%) patients developed AKI and 9 (17%) required renal replacement therapy (RRT) \[[@B6]\]. Higher morbidity has been reported among the elderly and in those with coexisting disease conditions \[[@B7]\]. With the increasing number of COVID-19 patients, the need for RRT is likely to increase. To prevent the spread of infection, all staff who managed CRRT wore personal protective equipment comprising standard, contact, and droplet precautions; gloves; N95 mask; gown; cap; and face shield. Although the recommendation by the WHO for the use of personal protective equipment for COVID-19 did not include CRRT \[[@B8]\], we considered the risk of aerosol generation during CRRT. The pore size of a hemofilter is 7--10 nm \[[@B9]\] and the size of 2019-nCoV is about 100 nm \[[@B10]\], which suggests that the permeability of 2019-nCoV into CRRT effluent is significantly low. Therefore, these results need to be evaluated in further studies. Additional examination including virus isolation should be considered to evaluate whether the effluent from CRRT is clinically infectious.

Conclusion {#sec1_4}
==========

To the best of our knowledge, this is the first report describing the management of CRRT including IPC among COVID-19 patients. From our experience, we suggest clinical practice and IPC for delivering RRT in the acute phase in COVID-19 patients who develop AKI (Table [2](#T2){ref-type="table"}).
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###### 

Clinical parameters and data

                         Day 1       Day 4   Day 7   Day 8   Day 9   Day 11   Day 14
  ---------------------- ----------- ------- ------- ------- ------- -------- --------
  Event                  Admission                   AKI     CRRT             
  sCre, mg/dL            1.34        1.34    1.25    2.08    3.46    4.52     6.21
  Urine volume, mL/day               2,240   864     558     398     20       7
  SOFA score                         11      13      14      15      21       15

                            Results of RT-PCR for SARS-CoV-2 (Ct)                                                                 
  ------------------------- --------------------------------------- ---------- --------- --------- --------- -------------------- --------------------
  Blood                     268.0                                   316.4      68.9      25.4      UD                             UD
                            (34.73)                                 (34.48)    (36.78)   (38.35)                                  
                                                                                                                                  
  Pharyngeal swab           1,766.0                                                                384.1                          20.5
                            (31.88)                                                                (31.4)                         (35.93)
                                                                                                                                  
  Lower respiratory tract   1,379,500.0                             48,200.0   4,586.0             466.7                          1,254.5
                            (21.81)                                 (26.88)    (30.43)             (31.11)                        (29.57)
                                                                                                                                  
  CRRT effluent                                                                                              1 h; 19.21 (36.05)   1 h; UD
                                                                                                             3 h; UD              3 h; 12.63 (37.45)
                                                                                                             6 h; 20.72 (35.91)   

CRRT effluent samples were taken on day 11 (1, 3, and 6 h after CRRT start) and on day 14 (1 and 3 h after CRRT start). Data are presented as virus copies per 1 µL (Ct). Lower cycle threshold (Ct) values indicate higher viral loads. RT-PCR was performed using Quantitect probe one-step RT-PCR kit (Qiagen, MD, USA) with the following probe and primer sets; WuhanCoV-spk2-f 5′-TTTCCTCGTGAAGGTGTCTTTGT-3′, WuhanCoV-spk2-r 5′-TGTGGTTCATAAAAATTCCTTTGTG-3′, and WuhanCoV-spk2-hex-p 5′-HEX-TCAAATG-GCACACACTGGTTTGT-BHQ1 targeting spike gene (24,843--24,916 in GenBank accession MN908947); WuhanCoV-N1f 5′-GGCCGCAAATTGCACAAT-3′, WuhanCoV-N1r 5′-CCAATGCGCGACATTCC-3′, and WuhanCoV-N1pr-fam 5′-FAM-CCCCCAGCGCTTCAGCGTTCT-TAMRA-3′ targeting nucleoprotein gene (29,191--29,251 in MN908947). SOFA, sequential organ failure assessment; CRRT, continuous renal replacement therapy; AKI, acute kidney injury; UD, undetected.

###### 

Clinical practice for CRRT for COVID-19

  Parameter                          Clinical practice
  ---------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Staff                              Certified doctor of blood purification in critical care
                                     
                                     Certified doctor of infectious disease
                                     
                                     Experienced medical engineers
                                     
                                     Highly trained ICU nurses
                                     
  Infection prevention and control   All staff who care for patient directly and handle CRRT equipment wear PPE: gloves, N95 mask, gown, cap, and face shield
                                     
                                     Patient is in an airborne infection isolation room at ICU, or designated ward
                                     
                                     CRRT equipment is placed in the anteroom during priming
                                     
  Access                             Temporary double-lumen catheter placed using ultrasound
                                     
  CRRT modality                      CRRT for initial treatment
                                     
                                     Consider transition to daytime RRT until recovery from AKI or can leave from biocontainment isolation
                                     
                                     PMMA or AN69ST membrane for initial hemofilter choice
                                     
  Replacement solution               Self-admixture sodium bicarbonate and sodium chloride solution (Na+ 140 mEq/L, K+ 2.0 mEq/L, Ca2+ 1.0 mEq/L, Mg2+ 1.0 mEq/L, Cl− 113 mEq/L, CH3COO− 0.5 mEq/L, HCO3− 35 mEq/L, and glucose 100 mg/dL)
                                     
  CRRT dosing                        Deliver a total effluent dose of 20 mL/kg per hour
                                     
                                     
  Anticoagulation                    Nafamostat mesylate 30--40 mg per hour
                                     
  Effluent disposal                  Drain patient-contact effluent in the container and add a coagulant before disposal
                                     
                                     Wipe outside of the container with alcohol, then treated as hazardous waste, and dispose

ICU, intensive care unit; CRRT, continuous renal replacement therapy; PPE, personal protective equipment; AKI, acute kidney injury; PMMA, polymethyl methacrylate; AS69ST, polyethylenimine-coated polyacrylonitrile.
